Today: 11 June 2026
ASX:PDI in focus after Robex shareholders back merger; approvals now in spotlight
1 January 2026
1 min read

ASX:PDI in focus after Robex shareholders back merger; approvals now in spotlight

NEW YORK, January 1, 2026, 09:22 ET — Market closed

Predictive Discovery Ltd said Robex Resources shareholders voted 94.54% in favour of the companies’ proposed merger, clearing a key condition for the all-share deal, an exchange filing showed. “We are delighted with the strong support shown by Robex shareholders for the Transaction,” CEO and Managing Director Andrew Pardey said, adding the combined group expects production of more than 400,000 ounces of gold a year by 2029. Predictive said the transaction is expected to close in the first quarter of 2026, subject to Québec court approval and regulatory consents, including from the governments of Guinea and Mali. company-announcements.afr.com

The vote moves the deal closer to completion after months of shifting expectations around one of the ASX’s more active gold situations. Investors now shift focus from shareholder support to execution risk and the timing of remaining sign-offs.

Cross-border mining mergers often hinge on approvals and funding, and all-share structures can keep prices jumpy as investors model dilution and closing risk. That matters because the value of what Robex holders receive will move with Predictive’s share price into completion.

Under the terms, Robex shareholders will receive 7.862 Predictive shares for each Robex share, valuing the deal at about A$2.17 billion ($1.45 billion), Reuters reported.

Perseus Mining’s A$2.1 billion bid for Predictive lapsed earlier in December after Robex tabled a superior offer, Reuters reported.

An all-share deal means investors are paid in stock rather than cash, so the effective price of the merger moves day by day. Traders who want the deal exposure without taking full market risk often hedge by selling the acquirer’s shares, which can weigh on the stock while approvals are pending.

Deal risk still sits in the driver’s seat. Any change to the expected timetable, or new disclosure around funding and development sequencing, is likely to show up quickly in the price.

Before the next session, Predictive shares last closed down 3.9% at A$0.735 on Dec. 31. The stock has traded between about A$0.63 and A$0.77 in December, leaving near-term support around A$0.70 and resistance near A$0.77.

Investors will watch for updates on the remaining approvals and for signals the closing schedule is holding. Any slippage tends to matter more in stock-based deals because the consideration is tied to the buyer’s shares.

Stock Market Today

  • Coupang Shares Rise After South Korea Imposes $410 Million Data Breach Fine
    June 11, 2026, 10:43 AM EDT. Coupang, the New York-listed South Korean e-commerce company, saw its shares rise 5.6% to $15.96 following a record $410 million fine from the Personal Information Protection Commission (PIPC) for a major data breach affecting over 37 million users. The fine includes penalties for a November 2025 incident and unauthorized data tracking via a third-party ad program. Coupang expects the penalty to impact its second-quarter operating expenses but plans to seek judicial relief. The regulator attributed the breach to a lack of proper safety measures, estimating the fine at approximately 1.4% of Coupang's 2025 revenue of 45 trillion won. Investors are monitoring whether this will lead to lasting effects on customer trust and profit margins.

Latest articles

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Redwire Stock Bounces as $500 Million Share Sale Draws Focus

Redwire Stock Bounces as $500 Million Share Sale Draws Focus

11 June 2026
Redwire stock jumped $1.24 to $16.11 Thursday after unveiling a $500 million at-the-market share sale, raising investor concerns about dilution versus growth funding; the new program could increase shares outstanding by about 11%, with the company’s 2026 revenue forecast and backlog now under scrutiny to justify the added supply.
Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Previous Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next
Next Story

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next

Go toTop